Q1 2025 Earnings Call Transcript April 25, 2025 AbbVie Inc. beats earnings expectations. Reported EPS is $2.46, expectations ...

AbbVie Inc. reports a strong Q1 2025 with EPS of $2.46 and raised guidance, fueled by Skyrizi, Rinvoq, and neuroscience growth.

AbbVie Inc.'s Q1 earnings highlight an 8.4% revenue boost, driven by Skyrizi & Rinvoq. Click for ABBV's market expansion, ...

AbbVie Inc (ABBV) surpasses expectations with robust sales growth in Skyrizi and Rinvoq, while navigating challenges in ...

In the Phase III SELECT-GCA trial, Rinvoq (upadacitinib) 15 mg with a 26-week glucocorticoid taper significantly improved ...

AbbVie raised its 2025 profit forecast on Friday after strong sales of its newer immunology drugs Skyrizi and Rinvoq helped ...

AbbVie stock climbs after Q1 earnings beat and 2025 EPS forecast raise; strong growth in immunology and neuroscience ...

The European Commission (“EC”) granted marketing approval to AbbVie’s Rinvoq for treating giant cell arteritis (“GCA”), an ...

For 2025, AbbVie forecast adjusted earnings per share at between $12.09 to $12.29, compared with earlier guidance in the range of $11.99 to $12.19. It noted that the current guidance is based on the ...

Despite the policy risks, AbbVie delivered a strong first quarter, posting adjusted earnings per share of $2.46, $0.10 above ...

While AbbVie handily beat expectations this quarter, the company faces declining Humira sales and a challenged aesthetics ...

Compounding the robust improvements in sales, AbbVie raised its profitability guidance for the full year. It now expects to post adjusted per-share earnings of $12.09 to $12.29; previously it was ...